Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab combination in advanced HER2-expressing gastric/GEJ cancer
NCT06650332Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2024
- Primary completion
- Aug 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of cadonilimab in gastric cancer (GC) and gastroesophageal junction cancer (3 cohorts), sponsored by Zhejiang Cancer Hospital. Primary endpoints: Dose Limiting Toxicity at 28 days and Objective Response Rate at 12 months. Started Jul 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT06650332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06650332.